Literature DB >> 10832596

Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines.

A Magklara1, L Grass, E P Diamandis.   

Abstract

We have investigated the steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in the breast cancer cell lines BT-474, T-47D, MFM-223, MCF-7, ZR-75-1, MDA-MB-435, and BT-20. Using highly sensitive time-resolved fluorometric immunoassays, we were able to detect significant amounts of both kallikreins in tissue culture supernatants of BT-474, T-47D, and MFM-223 cells after hormonal stimulation. However, BT-474 cells produce much more hK2 than PSA, whereas the situation is reversed in T-47D cells. Furthermore, BT-474 cells produce, on absolute terms, about 500-1,000-fold more hK2 than T-47D cells. From all steroids tested, mibolerone, a synthetic non-metabolizable androgen, was the most potent stimulator for both kallikreins followed by the synthetic progestin norgestrel. Estradiol was able to induce production of small but significant amounts of hK2 and PSA in the BT-474 cell line, supporting the notion that there is a cross-talk between the estrogen and androgen hormone-receptor signaling pathways. MFM-223 is an androgen responsive cell line, devoid of other steroid hormone receptors, which is also capable of producing hK2 and PSA but at much lower amounts. MCF-7 and ZR-75-1 cell lines failed to produce any protein, even though they have similar steroid receptor content as the BT-474 and T-47D cell lines. This was also the case for MDA-MB-435, a cell line rich in androgen receptors. Our data suggest that the expression of the hK2 gene in breast cancer cell lines is mainly under the control of androgens and progestins, similarly to PSA. These cell lines may represent good models for studying the differential expression of these two genes and for identifying cellular factors (e.g. co-activators/co-repressors), which may modify the potency of expression after hormonal stimulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10832596     DOI: 10.1023/a:1006304518750

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  16 in total

1.  Inferring higher functional information for RIKEN mouse full-length cDNA clones with FACTS.

Authors:  Takeshi Nagashima; Diego G Silva; Nikolai Petrovsky; Luis A Socha; Harukazu Suzuki; Rintaro Saito; Takeya Kasukawa; Igor V Kurochkin; Akihiko Konagaya; Christian Schönbach
Journal:  Genome Res       Date:  2003-06       Impact factor: 9.043

2.  Is Serum Prostate-specific Antigen a Diagnostic Marker for Benign and Malignant Breast Tumors in Women.

Authors:  Seyed Hasan Emami Razavi; Mahsa Ghajarzadeh; Alireza Abdollahi; Ludmila Taran; Saeed Shoar; Ramesh Omranipour
Journal:  Maedica (Buchar)       Date:  2015-06

3.  Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.

Authors:  Daniel L J Thorek; Philip A Watson; Sang-Gyu Lee; Anson T Ku; Stylianos Bournazos; Katharina Braun; Kwanghee Kim; Kjell Sjöström; Michael G Doran; Urpo Lamminmäki; Elmer Santos; Darren Veach; Mesruh Turkekul; Emily Casey; Jason S Lewis; Diane S Abou; Marise R H van Voss; Peter T Scardino; Sven-Erik Strand; Mary L Alpaugh; Howard I Scher; Hans Lilja; Steven M Larson; David Ulmert
Journal:  Sci Transl Med       Date:  2016-11-30       Impact factor: 17.956

4.  Serum total PSA and free PSA in breast tumors.

Authors:  Prakruti Dash; Sanghamitra Pati; Manaswini Mangaraj; Pratima Kumari Sahu; Prakash Chandra Mohapatra
Journal:  Indian J Clin Biochem       Date:  2011-02-04

5.  Equol, an isoflavone metabolite, regulates cancer cell viability and protein synthesis initiation via c-Myc and eIF4G.

Authors:  Columba de la Parra; Luis D Borrero-Garcia; Ailed Cruz-Collazo; Robert J Schneider; Suranganie Dharmawardhane
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

6.  Androgens act synergistically to enhance estrogen-induced upregulation of human tissue kallikreins 10, 11, and 14 in breast cancer cells via a membrane bound androgen receptor.

Authors:  Miltiadis Paliouras; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2008-01-09       Impact factor: 6.603

7.  Prostate-specific antigen is increased in female patients with Cushing's disease.

Authors:  L Manetti; I Lupi; F Bogazzi; G Pellegrini; A Precisi; L Grasso; C Nencetti; M Gasperi; E Martino
Journal:  J Endocrinol Invest       Date:  2002-10       Impact factor: 4.256

8.  The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.

Authors:  Joseph P Garay; Bedri Karakas; Abde M Abukhdeir; David P Cosgrove; John P Gustin; Michaela J Higgins; Hiroyuki Konishi; Yuko Konishi; Josh Lauring; Morassa Mohseni; Grace M Wang; Danijela Jelovac; Ashani Weeraratna; Cheryl A Sherman Baust; Patrice J Morin; Antoun Toubaji; Alan Meeker; Angelo M De Marzo; Gloria Lewis; Andrea Subhawong; Pedram Argani; Ben H Park
Journal:  Breast Cancer Res       Date:  2012-02-09       Impact factor: 6.466

9.  Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer.

Authors:  Edward R Sauter; David S Tichansky; Inna Chervoneva; Eleftherios P Diamandis
Journal:  Environ Health Perspect       Date:  2002-03       Impact factor: 9.031

10.  The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells.

Authors:  Radhika P Ghatge; Britta M Jacobsen; Stephanie A Schittone; Kathryn B Horwitz
Journal:  Breast Cancer Res       Date:  2005-11-02       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.